natgillin/translations-raw huggingface dataset:
The polypeptide expression system of claim 16, wherein the P1Prok2 is a selected from the group consisting of a PhoA promoter, a Tac promoter, and a Lac promoter. 
P1Prok2 je odabran iz skupine koja sadrži promotor PhoA, promotor Tac, promotor Lac; i/ili
The present invention further provides the inventive compounds for use in a method for treatment and/or prophylaxis of heart failure, pulmonary hypertension, chronic obstructive pulmonary disease, asthma, kidney failure, nephropathy, fibrotic disorders of the internal organs and dermatological fibroses. 
Spoj kako je definirano u bilo kojem od zahtjeva 1 do 11 naznačen time da je za uporabu u postupku za liječenje i/ili profilaksu zatajenja srca, plućne hipertenzije, kronične opstruktivne plućne bolesti, astme, zatajenja bubrega, nefropatije, fibroznih poremećaja unutarnjih organa i dermatoloških fibroza.
A compound as defined in claim 4 wherein R2 represents -CH2-CF3. 
Spoj u skladu s patentnim zahtjevom 4, naznačen time, da R2 predstavlja -CH2-CF3.
In some embodiments, Ring A is optionally substituted with 1 substituent. 
U nekim oblicima, Prsten A je po izboru supstituiran sa 1 supstituendom.
In some such embodiments, hydrophilic solvents of the present disclosure are selected from, but are not limited to diethylene glycol monoethyl ether, ethanol, glycerin, glycofurol, a MPEG, N-methyl-2-pyrrolidone, a PEG, propylene carbonate, propylene glycol, or a mixture of any two or more thereof. 
Formulacija prema zahtjevu 4, naznačena time, da hidrofilno otapalo je dietilen-glikol-monoetil eter, etanol, glicerin, glikofurol, metoksipolistilen glikol, N-metil-2-pirolidon, polietilen glikol, propilen karbonat, propilen glikol, ili mješavina od bilo koja dva ili više od istih.
An isolated nucleic acid vector comprising the isolated nucleic acid molecule according to claims 21 or 22. 
Izolirani vektor nukleinske kiseline koji sadrži izoliranu molekulu nukleinske kiseline prema patentnom zahtjevu 4.
The flask was sealed and placed under nitrogen then the flask was placed in an ice-water bath. 
Tikvica je bila začepljena i stavljena pod dušik i tada je tikvica bila stavljena u kupelj led/voda.
The recombinant nucleic acid of claim 6, wherein the nucleic acid sequence encodes a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 138, 140, and 142. 
Antitijelo prema patentnom zahtjevu 1 koje sadrži varijabilnu regiju lakog lanca (VL) koja sadrži aminokiselinsku sekvencu izabranu iz grupe koja se sastoji od SEQ ID NO: 138, 139, 140, 141, 142, 143, 144, 145, 146 i fragmenta istih.
is selected from C1-3alkyl, wherein said C1-3alkyl is optionally substituted by 1, 2 or 3 F and optionally by one substituent selected from OH, OC1-3alkyl, N(C1-3alkyl)2, cyclopropyl, or tetrahydropyran; 
je izabran od C1-3alkila, pri čemu je navedeni C1-3alkil izborno supstituiran s 1, 2 ili 3 F i izborno s jednim supstituentom odabranim od OH, OC1-3alkila, N(C1-3alkila)2, ciklopropila ili tetrahidropirana;
means for cooling the end (20) of the pipe (2) which at least use the process air; the machine being characterised in that: 
- < sredstava za hlađenje završetka (20) cijevi (2) koja koriste barem zrak za postupak; te je stroj naznačen time da:
Compound (I) can be used as an improving agent or an agent for the prophylaxis or treatment of diabetes, borderline type, impaired glucose tolerance, IFG (Impaired Fasting Glucose) and IFG (Impaired Fasting Glycemia) as defined by the above-mentioned new diagnostic criteria. 
Uporaba, naznačena time, da se koristi spoj prikazan formulom (1) iL) gdje R! je kao definiran u zahtjevu 1, ili njegova sol, u kombinaciji s pojačivačem osjetljivosti na inzulin, za proizvodnju sredstva za profilaksu ili liječenje cirkulacijskih oboljenja.
modulating the frames by an Orthogonal Frequency Division Multiplexing, OFDM, method; and 
demodulaciju primljenog signalnog okvira korištenjem metode multipleksiranja s ortogonalnom podjelom frekvencija (OFDM);
The packaged product according to any one of the preceding claims, wherein said beverage retains a foamy texture during at least 10 minutes after shaking. 
Pakirani proizvod u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što navedeni napitak zadržava pjenastu teksturu tijekom najmanje 10 minuta nakon tresenja.
The dose counter according to claim 1, wherein the actuator shaft is resiliently biased towards a starting position, the actuator shaft being displaceable against the resilient bias for actuating the dose counter. 
Brojač doza u skladu s bilo kojim od patentnih zahtjeva 1 ili 5, pri čemu je pokretačka osovina (20) elastično odmaknuta prema početnoj poziciji, pokretačka osovina (20) se može odmaknuti naspram elastičnog pomaka za pokretanje brojača doza.
For example, in certain embodiments, the solid support is a bead (e.g., a colloidal particle or a nanoparticle), a flow path in a lateral flow immunoassay device, a flow path in an analytical rotor, or a tube or a well (e.g., in a plate). 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što je površina put protoka u uređaju za ispitivanje s bočnim protokom ili put protoka u analitičkom rotoru, ili gdje je ispitivani uzorak tjelesna tekućina, ekstrakt tjelesnog organa, krv, serum ili plazma.
European Patent Application No. 
Broj europske prijave patenta:
The plant growing system according to claim 1, wherein said first guidance panel and said further guidance panel are arranged on top of a container, said container being adapted to accommodate plant roots that are controlled by said plant growing system and adapted to provide said plant roots with plant nutrients and/or water. 
Sustav za uzgajanje biljaka sukladno bilo kojem od zahtjeva 1 do 9, naznačen time što su navedeni prvi vodeći panel (1) i navedeni sljedeći vodeći panel (2) postavljeni na kontejner (3), pri čemu je navedeni kontejner prilagođen za smještaj korijenja biljaka koje kontrolira navedeni sustav za uzgajanje biljaka i prilagođen je za opskrbu navedenog korijenja biljaka nutrijentima za biljke i/ili vodom.
The compound for use according to the present invention is prepared in Example 48. 
Spoj ili farmaccutski sastav za uporabu prema zahtjevu 3, naznačen time, da bolcst ili poremećaj je rak pluća.
The process of claim 1, further comprising the steps of filtering, washing and drying said crystallized compound. The process of claim 1, wherein said solvent is water. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što dodatno sadrži korake filtriranja, ispiranja i sušenja navedenog kristaliziranog spoja.
the disorder is obesity; 
poremećaj je pretilost;
The process of claim 1, wherein the hydrogenation is performed with a catalyst and a hydrogen donor. 
Farmaceutski oblik doziranja prema patentnom zahtjevu 11 ili 12, naznačen time da u postupku redukcija jest hidrogenacija izvedena s katalizatorom i donorom vodika.
is the length of another pair of frame-members (H 2, H 4); and 
L, je dužina drugog para elemenata okvira (Ho, Hy); 1
applying a target double-stranded DNA to the solid support under conditions whereby the target DNA is fragmented by the transposome complexes, and the 3' transposon end sequence of the first polynucleotide is transferred to a 5' end of at least one strand of the fragments; thereby producing an immobilized library of double-stranded fragments wherein at least one strand is 5'-tagged with the first tag of the first sequence and at least one strand is 5'-tagged with the first tag of the second sequence. 
(b) stavljanju ciljane dvolančane DNA na čvrsti nosač u uvjetima u kojima se ciljanu DNA fragmentira transposomskim kompleksima, a terminalni slijed transposona na 3* kraju prvog polinukleotida se prebacuje na 5* kraj najmanje jednog lanca fragmenata; čime se dobiva imobiliziranu biblioteku dvolančanih fragmenata gdje je najmanje jedan lanac 5'-obilježeni prvim biljegom iz prvog slijeda, a najmanje jedan lanac je 5/- obilježeni prvim biljegom iz drugog slijeda.
Total uncoated tablet 
Ukupno neobložena tableta
In another embodiment in combination with any of the above or below embodiments, the disease is selected from non-malignant hyperproliferative disorders and malignant hyperproliferative disorders, specifically of hepatocellular carcinoma, colon adenoma and polyposis, colon adenocarcinoma, breast cancer, pancreas adenocarcinoma, Barrett's esophagus or other forms of neoplastic diseases of the gastrointestinal tract and the liver. 
Spoj za uporabu prema patentnom zahtjevu 10 naznačen time što je bolest izabrana od nemalignih hiperproliferativnih poremećaja i malignih hiperproliferativnih poremećaja, posebnoo hepatostaničnog karcinoma, adenoma debelog crijeva i polipoza, adenokarcinoma debelog crijeva, kancera dojke, adenokarcinoma pankreasa, Barett-ovog jednjaka ili drugih oblika neoplastičnih bolesti gastrointestinalnog trakta 1 jetre.
However, it should be clear to one skilled in the art that the formulation of the invention can also be used at lower concentrations of polypeptide such as e.g. from 1 to 10 mg/ml or from 1 to 20 mg/ml such as 1 mg/ml, 2 mg/ml, 5 mg/ml, 10 mg/ml, 15 mg/ml or 20 mg/ml. 
Formulacija prema bilo kojem od zahtjeva 1 do 3, naznačena time što - polipeptid ima topljivost od najmanje 20 mg/mL, poželjno 50 mg/mL ili više, poželjnije 90 mg/mL ili više ili 120 mg/mL, ili više, najpoželjnije 150 mg/mL ili više, ili čak 200 mg/mL, ili više, kako je određeno PEG postupkom isključivanja ili pokusom koncentracije;
The method of claim 1, wherein the single lysine residue is at a position corresponding to position 15 of SEQ ID NO: 1. 
Polipeptid klorotoksina prema bilo kojem prethodnom patentnom zahtjevu kome nedostaje najmanje jedna aminokiselina koja odgovara poziciji 15, 23, ili 27 sekvence SEQ ID NO: 1.
IDO is a 403 amino acid residue long polypeptide as disclosed in SEQ ID NO:1, and is the preferred IDO in the present text together with IDOLIKE of SEQ ID NO: 16). 
Izolirani peptid od najviše 25 uzastopnih aminokiselinskih ostataka sa SEQ ID NO:1, koji sadrži sekvencu SEQ ID NO:6.
The heat transport system of claim 3, wherein the reject heat exchanger comprises a plurality of fins, and wherein the fluid conduit is in conductive thermal communication with the plurality of fins. 
Sustav prijenosa topline prema zahtjevu 4, naznačen time, da povratni izmjenjivač topline obuhvaća mnoštvo peraja (305; 517), te time, da je u toplinskom vođenju fluidni cjevovod termalno povezan s mnoštvom peraja.
The genetically modified cell of embodiment 12, wherein the cell is a red blood cell (RBC). 
Genetski modificirana diferencirana stanica koja potječe od matične stanice prema patentnom zahtjevu 2, opcionalno pri čemu je stanica crvena krvna stanica (RBC).
The antibiotic macrolide of claim 1, wherein Y is S or SO2. 
Spoj u skladu s patentnim zahtjevom 1, gdje Y je S ili SO».
The method of claim 1, wherein the cytotoxic agent is selected from the group consisting of a toxin, a chemotherapeutic agent, a drug moiety, an antibiotic, a radioactive isotope, and a nucleolytic enzyme. 
Imunokonjugat, naznačen time, da sadrži protutijelo prema bilo kojem zahtjevu od 1 do 7 kovalentno priključeno na citotoksičko sredstvo, opcijski kemoterapeutsko sredstvo, funkcionalni dio lijeka, antibiotik, radioaktivni izotop, i nukleolitički enzim; ili
The integrated circuit according to claim 1 wherein the circuitry, in operation, controls transmission of assignment information indicating the allocated resource blocks to the terminal. 
Integrirani krug sukladno jednom od zahtjeva 1 do 5, naznačen time da su u prvoj dodjeli DVRB-ovi s uzastopnim DVRB brojevima dodijeljeni aparatu mobilnoj stanici.
N×(70 to 130) g/L PEG having an average molecular weight of 2500 to 4500; 
(a) 525 g/l polietilen-glikola (PEG) prosječne molekulske težine od 2500 do 4500;
converting the compound of formula VI" into the compound of formula VII by nitrosation. 
(ii) pretvaranje spoja formule VI'' u spoj formule VII putem nitrozacije.
A GLYX peptide for use as in any one of claims 1 to 3, wherein the effective amount is about 0.01 mg/kg to about 1000 mg/kg per day. 
GLYX-13 za primjenu u skladu sa zahtjevima 1 ili 2, naznačeno time da se GLYX-13 administrira u količini od 0.01 mg/kg do 1000 mg/kg na dan.
in part (d), the heavy chain comprises a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:119 and/or the light chain comprises a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:118; 
VH sekvencu koja ima najmanje 95% identiteta sekvence od aminokiselinske sekvence SEQ ID NO: 119 i VL sekvencu koja ima najmanje 95% identiteta sekvence od aminokiselinske sekvence SEQ ID NO: 118;
is a nitrogen atom, or is a methine or 1-vinyl-2-ylidene group optionally substituted by a hydroxyl group, a C1-6alkyl group or a hydroxy-C1-6alkyl group; 
je atom dušika, ili je metin ili 1-vinil-2-iliden skupina po izboru supstituirana hidroksil skupinom, nižom alkilnom skupinom ili hidroksi-nižom alkilnom skupinom;
Blade of a wind turbine according to any of the preceding claims comprising 2 fins and a base wherein the largest length in lateral direction in solid base material is less than 100% in particular less than 90% and more in particular less than 70% of the bottom fin chord. 
Lopatica vjetroturbine prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time da sadrži 2 peraje i bazu gdje je najveća dužina u bočnom smjeru u čvrstoj bazi manja od 100% naročito manja od 90% 1 više naročito manja od 70% donjeg dijela tetive peraja.
Use according to any one of claims 1 to 11, wherein the pharmaceutical composition further comprises an additional therapeutic compound, distinct from population of metallic nanoparticles, intended to treat cancer. Use according to any one of claims 1 to 12, wherein said mammalian cell is a human cell. 
Uporaba u skladu s patentnim zahtjevom I ili farmaceutski sastav za uporabu u skladu s patentnim zahtjevom 2, pri čemu farmaceutski sastav nadalje obuhvaća dodatnu terapijsku tvar namijenjenu za liječenje raka, navedena terapijska tvar je različita od populacije zlatnih nanočestica.
The zirconia particles must be of such a size and doping content that water phase transforms the particles. 
Čestice cirkonijeva oksida moraju biti takve veličine i sadržaja dopiranja da vodena faza transformira čestice.
administering to the subject a composition comprising: a therapeutically effective amount of soluble CD52 glycoprotein, wherein the soluble CD52 glycoprotein comprises the amino acid sequence GQNDTSQTSSPS (SEQ ID NO: 3), or 
Topljivi glikoprotein CD52, namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što topljivi glikoprotein CD52 sadrži aminokiselinski slijed GQNDTSQTSSPS (SEQ ID NO: 3) ili GQATTAASGTNKNSTSTKKTPLKS (SEQ ID NO: 5), te ugljikohidrat.
The cell culture supernatant of claim 1, wherein the one or more cell is cultured in at least 100 L of the supplemented basal cell culture media. The cell culture supernatant of claim 1, where the cell density is maintained at less than 2.5×106 cells per mL during the step of culturing the one or more cells. The cell culture supernatant of claim 23, where the cell density is maintained at less than 2.0×106 cells per mL during the step of culturing the one or more cells. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačen time što se jednu ili više stanica uzgaja u najmanje 100 1 kompletiranog osnovnog medija za uzgoj stanica. Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačen time što se gustoću stanica održava kod manje od 2,5 x 10" stanica na ml u koraku uzgoja jedne ili više stanica, manje od 2,0 x 10" stanica na ml u koraku uzgoja jedne ili više stanica, ili manje od 1,5 x 10" stanica na ml u koraku uzgoja jedne ili više stanica.
The compound for use of claim 13, wherein the condition is gout, a recurrent gout attack, gouty arthritis, hyperuricaemia, hypertension, a cardiovascular disease, coronary heart disease, Lesch-Nyhan syndrome, Kelley-Seegmiller syndrome, kidney disease, kidney stones, kidney failure, joint inflammation, arthritis, urolithiasis, plumbism, hyperparathyroidism, psoriasis, sarcoidosis, hypoxanthine-guanine phosphoribosyltransferase (HPRT) deficiency or a combination thereof. 
Spoj prema zahtjevu 1 ili zahtjevu 2, za upotrebu prema zahtjevu 8, naznačen time da stanje je giht, povratni napad gihta, gihtični artritis, hiperuricemija, hipertenzija, kardiovaskularna bolest, koronarna srčana bolest, Lesch-Nyhanov sindrom, Kelley-Seegmillerov sindrom, bolest bubrega, bubrežni kamenci, zatajenje bubrega, upala zglobova, artritis, urolitijaza, plumbizam, hiperparatireoidizam, psorijaza, sarkoidoza, nedostatak hipoksantin-gvanin-fosforiboziltransferaze (HPRT) ili njihove kombinacije.
The pharmaceutical composition according to claim 2, wherein said pharmaceutical composition further comprises one or more additional therapeutic agents. 
Farmaceutski sastav prema zahtjevu 4, pri čemu spomenuti sastav dalje sadrži jedno ili više dodatnih terapeutskih sredstava.
A compound according to claim 1 which is 4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]furo[3,4-b]pyridin-5(7H)-one or a pharmaceutically acceptable salt thereof. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je 9-[3-(4-fluorfenil)-1-metil-1H-pirazol-4-il]-2-metil-2,3,4,5-tetrahidropirido[2,3-f][1,4]oksazepin, ili njegova farmaceutski prihvatljiva sol.
is selected from the group consisting of methyl, isopropyl, cyclopentyl, cyclopropyl, 2-furanyl, trifluommethyl, methoxymethyl, aminomethyl, dimethylaminomethyl, dimethylamino-1-ethyl, 1-dimethylamino-ethyl, and 2-dimethylamino-ethyl, wherein R2 is optionally substituted with deuterium; 
R? je odabran iz skupine koja sadrži metil, izopropil, ciklopentil, ciklopropil, 2-furanil, trifluorometil, metoksimetil, aminometil, dimetilaminometil, dimetilamino-1-etil, 1-dimetilamino-etil, i 2-dimelilamino-etil, pri čemu R? je proizvoljno supstituiran sa deuterijem;
The pharmaceutical composition according to claim 9, further comprising a pharmaceutically acceptable carrier. 
Farmaceutski pripravak prema zahtjevu 12, koji nadalje sadrži farmaceutski prihvatljiv nosač.
is an optionally substituted group selected from straight or branched (C1-C8) alkyl, (C3-C8) cylcoalkyl, (C3-C8) cycloalkenyl, heterocyclyl, aryl and heteroaryl; or a pharmaceutically acceptable salt thereof. 
R7 je izborno supstituirana skupina, koju se bira između nerazgranatog ili razgranatog (C;-Cg) alkila, (C2-Cg) cikloalkila, (C3-Cg) cikloalkenila, heterociklila, arila i heteroarila.
the eluate from the previous step is passed again through a diatomaceous earth column; the columns are washed with a solution as per in step f), and phycotoxins are eluted with an extraction solution; 
eluat iz prethodnog koraka se propušta ponovno kroz kolonu dijatomejske zemlje; kolone se ispiru otopinom kao u koraku f), i fikotoksini se eluiraju ekstrakcijskom otopinom;
The jacketed tube of claim 1 further comprising a jacket of one or more materials of a group consisting of polyethylene, ethylene chlorotrifluoroerthlyene, a thermoplastic elastomer cross linking ethylene propylene diene monomer rubber and polypropylene, perfluoroalkoxy, polyvinylidene fluoride and fluorinated ethylene propylene wherein the material is extruded onto the tube without radiation curing. 
Obložena cijev u skladu s patentnim zahtjevom 1, naznačena time što dodatno sadrži oblogu od jednog ili više materijala iz skupine koju čine polietilen, etilen-klortrifluoretilen, termoplastični elastomerni umreženi etilenpropilen-dien-monomer-kaučuk i polipropilen, perfluoralkoksi, poliviniliden-fluorid 1 fluorirani etilen-propilen, gdje se materijal ekstrudira na cijev bez stvrdnjavanja uz pomoć zračenja.
The resulting suspension was filtered and washed with water to give a clear beige solid. 
Nastala suspenzija se profiltrira i ispere s vodom da se dobije prozirna krutina bež boje.
wherein X2 is —O— or —S—, n3 is an integer from 1 to 6, preferably from 1 to 4, R2 is as defined above; wherein: 
Re -(CH-CH-ArrCH,-CH i gdje X, jest ili -S-, n' je cijeli broj od 1 do 6, a R? je kao što je gore definiran, h)
adding biotinylated natalizumab to the samples in the assay wells; and detecting the biotinylated natalizumab using a horse radish peroxidase assay. 
dodavanja biotiniliranog natalizumaba uzorcima u ispitnim jažicama; i detektiranja biotiniliranog natalizumaba ispitivanjem peroksidazom iz hrena.
To 2100 ml of methanol was added 60.0 g of nebivolol hydrochloride at room temperature. 
Ovome je polagano dodano 88 ml piperidina na sobnoj temperaturi te je miješano tijekom 30 minuta.
In a variation, the effluent obtained in step a) undergoes a separation step in order to separate a heavy fraction and a light fraction containing the H2S and NH3 formed during step a), said heavy fraction then being introduced into step b). 
Postupak prema jednom od zahtjeva 1 do 12, naznačen time da se efluent dobiven u koraku a) podvrgava koraku odvajanja kako bi se odvojila teška frakcija i lagana frakcija koje sadrže H,S i NH> koji nastaje tijekom koraka a), navedena teška frakcija se zatim uvodi u korak b).
The composition according to claim 3, wherein the drug/polymer mass ratio is about 33%. 
Sastav u skladu s patentnim zahtjevima 1 ili 2, naznačen time što je omjer mase lijeka/polimera otprilike 33%.
SEC analysis at M3 of: monomer content greater than about 90%; aggregates content of less than about 3 wt %; and fragment 3 content less than about 5 wt %: and 
SEC analizom u T> sa: sadržajem monomera većim od 90%; sadržajem agregata od manje od 3 tež%; 1 sadržajem fragmenta 3 manjim od 5 tež%.
Process a) reaction of a pyrimidine of formula (II): wherein L is a displaceable group; with an pyrazole amine of formula (III): or 
Postupak a) reakcija pirimidina formule (II): gdje je L zamjenjiva grupa; sa pirazol aminom formule (III): HR P20090454 TI ili
The reaction was heated to 70°C. The reaction was stirred at 70 °C for 24 hours. 
Reakcijska smjesa je bila zagrijana do 70*C. Reakcijska smjesa je bila miješana pri 70*C 24 sata.
The mixture is then processed into granules or pressed into tablets. 
Mješavina je tada procesuirana u granule ili stisnuta u tablete.
wherein the extended release matrix formulation is cured at a temperature of at least about 60 °C for a time period of at least about 1 minute and has a cracking force of at least about 110 N when subjected to an indentation test. 
Postupak prema zahtjevu 6, naznačen time da se formulacija matrice s produljenim otpuštanjem podvrgava temperaturi od barem oko 62 °C ili barem oko 68 °C u vremenskom periodu od oko 1 minute do oko 5 sati ili od oko 5 minuta do oko 3 sata.
The method of claim 2, wherein if the biological sample is positive for JCV antibody then the subject is at an increased risk of PML as compared to a subject who is negative for a JCV antibody. 
Postupak u skladu s patentnim zahtjevom 1 ili 2, naznačen time što detektiranje protutijela protiv ICV koja se vežu na HPVLP-e ukazuje da subjekt: (1) je pod povišenim rizikom od PML ako je biološki uzorak pozitivan na protutijelo protiv JCYV; ili
putting a plurality of modules onto a pallet; and fixing the modules on the pallet, preferably by wrapping a further plastic film around the package. 
(6) učvršćivanje modula (6) na paletu (8), poželjno je omatanjem dodatne plastične folije (9) oko paketa.
The composition according to Embodiment 11 wherein said peptide is linked to a carrier molecule such as BSA or KLH and/or is comprised in a lipid composition such as a lipid particle, a nanocapsule, a liposome or lipid vesicles with a pharmaceutical excipient. 
Farmaceutski pripravak prema zahtjevu 5, naznačen time da (i) navedeni peptid može biti vezan za molekulu nosača i/ili se nalazi u lipidnom pripravku s farmaceutskim ekscipijentom; i/ili (ii) pripravak sadrži barem još drugo anti-kancerogeno sredstvo.
The composition according to embodiment 9, wherein the pH adjusting substance is sodium carbonate. 
Pripravak prema zahtjevu 9, naznačen time da tvar za prilagođavanje pH je natrij karbonat.
Blocking buffer—BSA Diluent/Blocking solution concentrate (3.1.50) diluted 1:10. 
Pufer za blokiranje - koncentrat BSA diluent/otopina za blokiranje (3.1.50) razrijeđeno u omjeru 1:10.